ADCT - Wutah dodolan YoY sajrone 12 wulan kepungkur ADC Pharma

Logo perusahaan publik ADC Pharma (ADCT)

ADC Therapeutics is investing significant resources into developing advanced conjugates for hematologic malignancy therapies, striving for technological leadership. However, the sector entails high risks and fierce market competition with biotech behemoths. Comparable year-over-year sales growth over 12 months demonstrates current revenue dynamics, where the indicator level stands at 13.10. Raw material supplies are reliably distributed between Europe and the US.

ADCT Wutah pendapatan YoY sajrone 12 wulan kepungkur ADC Therapeutics S.A. (11.02.2024 - 18.11.2026)

ADC Therapeutics SA (ADCT) - rincian metrik lan laporan keuangan

Ringkesan analitik perusahaan:ADC Therapeutics
Sampel barang adctherapeutics.com

The sales dynamics of Zynlonta for lymphoma therapy determine the trajectory of the TTM year-over-year revenue chart for ADC Therapeutics (ADCT), reflecting the product's penetration rate into the insurance reimbursement market. This indicator measures the percentage deviation of current aggregate revenue from the previous year's figures, allowing for the filtering of short-term volatility and the assessment of the company's fundamental operating capacity through the lens of the cost of capital.